Olgu Sunumu
BibTex RIS Kaynak Göster

Yıl 2018, Cilt: 35 Sayı: 1, 27 - 30, 25.10.2019

Murat Terzi Taşkın Duman Sedat Şen Murat Güntel Nalan Örtücü Şen

Öz

Kaynakça

  • Ahmed, A.M., Brantley, J.S., Madkan, V., Mendoza, N., Tyring, S.K., 2007. Managing herpes zoster in immunocompromised patients. Herpes. 14, 32-6.
  • Bennett, G.J., 1994. Hypotheses on the pathogenesis of herpes zoster associated pain. Ann Neurol. 35, 38-41.
  • Brody, M.B., Moyer, D., 1997. Varicella-zoster virus infection. Postgrad Med. 102(1), 187–94.
  • Cohen, J.I., Brunell, P.A., Straus, S.E., Krause, P.R., 1999. Recent advances in varicella-zoster virus infection. Ann Intern Med.130, 922-32.
  • Cohen, J.A., Barkhof, F., Comi, G., Hartung, H.P., Khatri, B.O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., Tiel-Wilck, K., de Vera, A., Jin, J., Stites, T., Wu, S., Aradhye, S., Kappos, L., Transforms Study Group., 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 362, 402-15.
  • Dworkin, R.H., Johnson, R.W., Breuer, J., Gnann, J.W., Levin, M.J., Backonja, M., Betts, R.F., Gershon, A.A., Haanpaa, M.L., McKendrick, M.W., Nurmikko, T.J., Oaklander, A.L., Oxman, M.N., Pavan-Langston, D., Petersen, K.L., Rowbotham, M.C., Schmader, K.E., Stacey, B.R., Tyring, S.K., van Wijck, A.J., Wallace, M.S., Wassilew, S.W., Whitley, R.J., 2007. Recommendations for the management of herpes zoster. Clin Infect Dis. 44(1), 1-26.
  • Gnann, J.W. Jr., Whitley, R.J., 2002. Clinical practice: herpes zoster. N Engl J Med. 347, 340-6. Kappos, L., Radue, E.W., O’Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang- Auberson, L., Burtin, P., Freedoms Study Group., 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 362, 387-401.
  • Ricklin, M.E., Lorscheider, J., Waschbisch, A., Paroz, C., Mehta, S.K., Pierson, D.L., Kuhle, J., Fischer-Barnicol, B., Sprenger, T., Lindberg, R.L., Kappos, L., Derfuss, T., 2013. T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology. 9, 81(2), 174-81.
  • Strauss, S.E., 1994. Overview: the biology of varicella-zoster virus infection. Ann Neurol. 35, 4–8.
  • Uccelli, A., Ginocchio, F., Mancardi, G.L., Bassetti, M., 2011. Primary varicella zoster infection associated with fingolimod treatment.Neurology. 15, 76(11), 1023-4.
  • Weinberg, J.M., 2007. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol. 57, 130-5. Winkelmann, A., Löbermann, M., Reisinger, E.C., Zettl, U.K. 2012. Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations. Nervenarzt. 83(2), 236-42.

Two multiple sclerosis cases developed herpes zoster during use of fingolimod

Yıl 2018, Cilt: 35 Sayı: 1, 27 - 30, 25.10.2019

Murat Terzi Taşkın Duman Sedat Şen Murat Güntel Nalan Örtücü Şen

Öz




Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central
nervous system. Immunosuppressive and immunomodulating drugs are used
during disease monitoring. Fingolimod is one of the immunomodulatory treat-
ments used in MS patients. It is a therapeutic agent acting on lymphocytes. La-
tent varicella-zoster virus infections may occur in MS patients receiving fingo-
limod therapy. In this article, the information of two cases with varicella-zoster
virus reactivation during fingolimod use were presented.




Anahtar Kelimeler

Fingolimod Multiple sclerosis Varicella-zoster virus reactivation Zoster

Kaynakça

  • Ahmed, A.M., Brantley, J.S., Madkan, V., Mendoza, N., Tyring, S.K., 2007. Managing herpes zoster in immunocompromised patients. Herpes. 14, 32-6.
  • Bennett, G.J., 1994. Hypotheses on the pathogenesis of herpes zoster associated pain. Ann Neurol. 35, 38-41.
  • Brody, M.B., Moyer, D., 1997. Varicella-zoster virus infection. Postgrad Med. 102(1), 187–94.
  • Cohen, J.I., Brunell, P.A., Straus, S.E., Krause, P.R., 1999. Recent advances in varicella-zoster virus infection. Ann Intern Med.130, 922-32.
  • Cohen, J.A., Barkhof, F., Comi, G., Hartung, H.P., Khatri, B.O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., Tiel-Wilck, K., de Vera, A., Jin, J., Stites, T., Wu, S., Aradhye, S., Kappos, L., Transforms Study Group., 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 362, 402-15.
  • Dworkin, R.H., Johnson, R.W., Breuer, J., Gnann, J.W., Levin, M.J., Backonja, M., Betts, R.F., Gershon, A.A., Haanpaa, M.L., McKendrick, M.W., Nurmikko, T.J., Oaklander, A.L., Oxman, M.N., Pavan-Langston, D., Petersen, K.L., Rowbotham, M.C., Schmader, K.E., Stacey, B.R., Tyring, S.K., van Wijck, A.J., Wallace, M.S., Wassilew, S.W., Whitley, R.J., 2007. Recommendations for the management of herpes zoster. Clin Infect Dis. 44(1), 1-26.
  • Gnann, J.W. Jr., Whitley, R.J., 2002. Clinical practice: herpes zoster. N Engl J Med. 347, 340-6. Kappos, L., Radue, E.W., O’Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang- Auberson, L., Burtin, P., Freedoms Study Group., 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 362, 387-401.
  • Ricklin, M.E., Lorscheider, J., Waschbisch, A., Paroz, C., Mehta, S.K., Pierson, D.L., Kuhle, J., Fischer-Barnicol, B., Sprenger, T., Lindberg, R.L., Kappos, L., Derfuss, T., 2013. T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology. 9, 81(2), 174-81.
  • Strauss, S.E., 1994. Overview: the biology of varicella-zoster virus infection. Ann Neurol. 35, 4–8.
  • Uccelli, A., Ginocchio, F., Mancardi, G.L., Bassetti, M., 2011. Primary varicella zoster infection associated with fingolimod treatment.Neurology. 15, 76(11), 1023-4.
  • Weinberg, J.M., 2007. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol. 57, 130-5. Winkelmann, A., Löbermann, M., Reisinger, E.C., Zettl, U.K. 2012. Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations. Nervenarzt. 83(2), 236-42.
Toplam 11 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Bölüm Case Report
Yazarlar

Murat Terzi

Taşkın Duman Bu kişi benim

Sedat Şen Bu kişi benim

Murat Güntel Bu kişi benim

Nalan Örtücü Şen Bu kişi benim

Yayımlanma Tarihi 25 Ekim 2019
Gönderilme Tarihi 10 Aralık 2015
Kabul Tarihi 28 Şubat 2016
Yayımlandığı Sayı Yıl 2018 Cilt: 35 Sayı: 1

Kaynak Göster

APA Terzi, M., Duman, T., Şen, S., Güntel, M., vd. (2019). Two multiple sclerosis cases developed herpes zoster during use of fingolimod. Journal of Experimental and Clinical Medicine, 35(1), 27-30.
AMA Terzi M, Duman T, Şen S, Güntel M, Örtücü Şen N. Two multiple sclerosis cases developed herpes zoster during use of fingolimod. J. Exp. Clin. Med. Ekim 2019;35(1):27-30.
Chicago Terzi, Murat, Duman Taşkın, Sedat Şen, Murat Güntel, ve Örtücü Şen Nalan. “Two Multiple Sclerosis Cases Developed Herpes Zoster During Use of Fingolimod”. Journal of Experimental and Clinical Medicine 35, sy. 1 (Ekim 2019): 27-30.
EndNote Terzi M, Duman T, Şen S, Güntel M, Örtücü Şen N (01 Ekim 2019) Two multiple sclerosis cases developed herpes zoster during use of fingolimod. Journal of Experimental and Clinical Medicine 35 1 27–30.
IEEE M. Terzi, T. Duman, S. Şen, M. Güntel, ve Örtücü Şen N., “Two multiple sclerosis cases developed herpes zoster during use of fingolimod”, J. Exp. Clin. Med., c. 35, sy. 1, ss. 27–30, 2019.
ISNAD Terzi, Murat vd. “Two Multiple Sclerosis Cases Developed Herpes Zoster During Use of Fingolimod”. Journal of Experimental and Clinical Medicine 35/1 (Ekim 2019), 27-30.
JAMA Terzi M, Duman T, Şen S, Güntel M, Örtücü Şen N. Two multiple sclerosis cases developed herpes zoster during use of fingolimod. J. Exp. Clin. Med. 2019;35:27–30.
MLA Terzi, Murat vd. “Two Multiple Sclerosis Cases Developed Herpes Zoster During Use of Fingolimod”. Journal of Experimental and Clinical Medicine, c. 35, sy. 1, 2019, ss. 27-30.
Vancouver Terzi M, Duman T, Şen S, Güntel M, Örtücü Şen N. Two multiple sclerosis cases developed herpes zoster during use of fingolimod. J. Exp. Clin. Med. 2019;35(1):27-30.
 Kapak Resmi İndir

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.